SG10201900564WA - Methods for treating cancer - Google Patents

Methods for treating cancer

Info

Publication number
SG10201900564WA
SG10201900564WA SG10201900564WA SG10201900564WA SG10201900564WA SG 10201900564W A SG10201900564W A SG 10201900564WA SG 10201900564W A SG10201900564W A SG 10201900564WA SG 10201900564W A SG10201900564W A SG 10201900564WA SG 10201900564W A SG10201900564W A SG 10201900564WA
Authority
SG
Singapore
Prior art keywords
methods
treating cancer
compound
kits
administering
Prior art date
Application number
SG10201900564WA
Inventor
Chiang Li
Wei Li
Youzhi Li
Matthew Hitron
Yuan Gao
Original Assignee
Boston Biomedical Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boston Biomedical Inc filed Critical Boston Biomedical Inc
Publication of SG10201900564WA publication Critical patent/SG10201900564WA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Methods for Treating Cancer Methods comprising administering and kits comprising at least one paclitaxel compound and at least one compound of formula (I) (I). (no drawing to be published)
SG10201900564WA 2015-04-17 2016-04-18 Methods for treating cancer SG10201900564WA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562149349P 2015-04-17 2015-04-17
US201662280947P 2016-01-20 2016-01-20

Publications (1)

Publication Number Publication Date
SG10201900564WA true SG10201900564WA (en) 2019-02-27

Family

ID=55854799

Family Applications (2)

Application Number Title Priority Date Filing Date
SG11201708504XA SG11201708504XA (en) 2015-04-17 2016-04-18 Methods for treating cancer
SG10201900564WA SG10201900564WA (en) 2015-04-17 2016-04-18 Methods for treating cancer

Family Applications Before (1)

Application Number Title Priority Date Filing Date
SG11201708504XA SG11201708504XA (en) 2015-04-17 2016-04-18 Methods for treating cancer

Country Status (16)

Country Link
US (1) US20180085341A1 (en)
EP (1) EP3283069A1 (en)
JP (1) JP2018511643A (en)
KR (1) KR20180006918A (en)
CN (1) CN107666906A (en)
AU (1) AU2016247319A1 (en)
BR (1) BR112017022281A2 (en)
CA (1) CA2983010A1 (en)
EA (1) EA201792287A1 (en)
HK (1) HK1250944A1 (en)
IL (1) IL255022A0 (en)
MX (1) MX2017013360A (en)
PH (1) PH12017501879A1 (en)
SG (2) SG11201708504XA (en)
TW (1) TW201713327A (en)
WO (1) WO2016168856A1 (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009036099A1 (en) 2007-09-10 2009-03-19 Boston Biomedical, Inc. A novel group of stat3 pathway inhibitors and cancer stem cell pathway inhibitors
SG11201508358RA (en) 2013-04-09 2015-11-27 Boston Biomedical Inc 2-acetylnaphtho[2,3-b]furan -4,9-dione for use on treating cancer
CN109069469A (en) * 2016-01-20 2018-12-21 北京强新生物科技有限公司 The method for the treatment of cancer
CA3045306A1 (en) 2016-11-29 2018-06-07 Boston Biomedical, Inc. Naphthofuran derivatives, preparation, and methods of use thereof
JP2020520923A (en) 2017-05-17 2020-07-16 ボストン バイオメディカル， インコーポレイテッド Methods for treating cancer
US11452727B2 (en) * 2017-09-05 2022-09-27 Epizyme, Inc. Combination therapy for treating cancer
MX2021004151A (en) * 2018-10-12 2021-09-08 1Globe Biomedical Co Ltd New combination solution for treating chemotherapy refractory cancer.
US20220170940A1 (en) * 2019-03-27 2022-06-02 Singapore Health Services Pte Ltd Biomarker with therapeutic implications for peritoneal carcinomatosis

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009036099A1 (en) 2007-09-10 2009-03-19 Boston Biomedical, Inc. A novel group of stat3 pathway inhibitors and cancer stem cell pathway inhibitors
RU2591823C2 (en) 2010-03-19 2016-07-20 Бостон Байомедикал, Инк. Novel methods for targeting cancer stem cells
BR122021025776B1 (en) 2010-03-19 2022-12-27 Boston Biomedical, Inc. COMPOSITION COMPRISING NAPHTOFURAN COMPOUNDS AND THEIR USE TO TREAT CANCER
CN103402993A (en) 2011-03-04 2013-11-20 舟山海中洲新生药业有限公司 Novel esters of 4,9-dihydroxy-naphtho[2,3-b]furans for disease therapies
US8977803B2 (en) 2011-11-21 2015-03-10 Western Digital Technologies, Inc. Disk drive data caching using a multi-tiered memory
WO2013166618A1 (en) * 2012-05-08 2013-11-14 Zhoushan Haizhongzhou Xinsheng Pharmaceuticals Co., Ltd. PRODRUGS OF 4,9-DIHYDROXY-NAPHTHO[2,3-b]FURANS FOR CIRCUMVENTING CANCER MULTIDRUG RESISTANCE
SG11201508358RA (en) * 2013-04-09 2015-11-27 Boston Biomedical Inc 2-acetylnaphtho[2,3-b]furan -4,9-dione for use on treating cancer

Also Published As

Publication number Publication date
IL255022A0 (en) 2017-12-31
AU2016247319A1 (en) 2017-11-02
EP3283069A1 (en) 2018-02-21
PH12017501879A1 (en) 2018-03-05
CN107666906A (en) 2018-02-06
BR112017022281A2 (en) 2018-07-10
HK1250944A1 (en) 2019-01-18
EA201792287A1 (en) 2018-03-30
SG11201708504XA (en) 2017-11-29
CA2983010A1 (en) 2016-10-20
WO2016168856A1 (en) 2016-10-20
KR20180006918A (en) 2018-01-19
JP2018511643A (en) 2018-04-26
US20180085341A1 (en) 2018-03-29
TW201713327A (en) 2017-04-16
MX2017013360A (en) 2018-08-01

Similar Documents

Publication Publication Date Title
SG10201900564WA (en) Methods for treating cancer
MY198613A (en) Nitrobenzyl derivatives of anti-cancer agents
MX2020003702A (en) Cyclopropylamines as lsd1 inhibitors.
IL253979A0 (en) Methods, compositions, and kits for treatment of cancer
NZ724691A (en) Quinoline derivatives as smo inhibitors
MX2016002544A (en) Compounds useful as immunomodulators.
PH12015501576A1 (en) Substituted pyrrolopyrimidine compounds, compositions thereof, and methods of treatment therewith
WO2014164704A3 (en) Compounds and compositions for the treatment of cancer
PH12015501997A1 (en) Compositions and methods for diagnosis and treatment of hepatic cancers
MX2016009590A (en) Apilimod compositions and methods for using same.
MX2018000715A (en) Methods for treating cancer using apilimod.
MX2016009663A (en) Icariin derivatives.
MX2019013808A (en) Compounds for treatment of cancer.
MX2017000312A (en) Isoindoline derivatives for use in the treatment of a viral infection.
CL2015002116A1 (en) Administration of anti-activin-a compound to a subject
MX2016006975A (en) Compounds, pharmaceutical composition and methods for use in treating inflammatory diseases.
MX2017006026A (en) Apilimod for use in the treatment of colorectal cancer.
PH12017501880A1 (en) Methods for treating cancer
MX2016005393A (en) Methods for treating hcv.
JO3541B1 (en) Medical treatments based on anamorelin
NZ740817A (en) Pcna inhibitors
MX2015013021A (en) 5-bromo-indirubins.
MX2015012523A (en) Methods of making cancer compositions.
CY1125266T1 (en) RAD1901 FOR USE IN THE TREATMENT OF OVARIAN CANCER
NZ779760A (en) Pcna inhibitors